FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2031848840> ?p ?o ?g. }

• W2031848840 endingPage "2418" @default.
• W2031848840 startingPage "2411" @default.
• W2031848840 abstract "Secretory phospholipase A(2) (sPLA(2)) may play a role in myonecrosis after elective percutaneous coronary intervention (PCI). Inhibition of this enzyme may have a beneficial effect. The central hypothesis of this study was that treatment with varespladib, a small-molecule inhibitor of sPLA(2) would reduce postprocedural release of cardiac biomarkers after elective percutaneous coronary intervention.Between October 2007 and June 2009, 144 stable patients were randomized in a phase II trial to receive varespladib 500 mg PO BID or placebo 3 to 5 days before and for 5 days after elective percutaneous coronary intervention. The primary end point was elevation of troponin I or creatine kinase-MB above the upper limit of normal at 6 to 8 or 18 to 24 hours after percutaneous coronary intervention. Mean age was 63±10 and 64±10 years, with 38% and 42% with diabetes mellitus and 29% and 28% with prior myocardial infarction for the varespladib and placebo groups, respectively. The primary end point occurred in 75% of varespladib and 63% of placebo patients (P=0.14). Troponin I 3 times the upper limit of normal was observed in 57% and 50% (P=0.39) and creatine kinase-MB 2 times the upper limit of normal in 14% and 3% (P=0.018). Median (first and third quartiles) change in high-sensitivity C-reactive protein in these 2 groups was 0.65 mg/L (-0.18 and 1.48) and 0.70 mg/L (0.00 and 1.50) at 18 to 24 hours (P=0.81) and 0.20 mg/L (-0.70 and 1.40) and 0.60 mg/L (-0.12 and 1.72) at 3 to 5 days (P=0.23), whereas change in sPLA(2) activity at 3 to 5 days in a subset was -2.85 ng/ml (-3.40 and -1.85) and 0.25 ng/ml (-0.20 and 0.85) (P<0.001).Inhibition of sPLA(2) by varespladib administered for 3 to 5 days before the procedure does not reduce periprocedural myonecrosis associated with elective percutaneous coronary intervention.URL: http://www.clinicaltrials.gov. Unique identifier: NCT00533039." @default.
• W2031848840 created "2016-06-24" @default.
• W2031848840 creator A5012456201 @default.
• W2031848840 creator A5012706547 @default.
• W2031848840 creator A5016716924 @default.
• W2031848840 creator A5021133301 @default.
• W2031848840 creator A5022002853 @default.
• W2031848840 creator A5024193392 @default.
• W2031848840 creator A5027291703 @default.
• W2031848840 creator A5039972459 @default.
• W2031848840 creator A5048687590 @default.
• W2031848840 creator A5070754331 @default.
• W2031848840 creator A5072521028 @default.
• W2031848840 creator A5083447391 @default.
• W2031848840 creator A5089017943 @default.
• W2031848840 date "2010-12-07" @default.
• W2031848840 modified "2023-10-17" @default.
• W2031848840 title "The sPLA ₂ Inhibition to Decrease Enzyme Release After Percutaneous Coronary Intervention (SPIDER-PCI) Trial" @default.
• W2031848840 cites W1969148674 @default.
• W2031848840 cites W1974113459 @default.
• W2031848840 cites W1979691471 @default.
• W2031848840 cites W1986097045 @default.
• W2031848840 cites W1992850917 @default.
• W2031848840 cites W2006014301 @default.
• W2031848840 cites W2020420784 @default.
• W2031848840 cites W2043612631 @default.
• W2031848840 cites W2045467069 @default.
• W2031848840 cites W2056715903 @default.
• W2031848840 cites W2064226555 @default.
• W2031848840 cites W2077014318 @default.
• W2031848840 cites W2081953245 @default.
• W2031848840 cites W2094653215 @default.
• W2031848840 cites W2098885552 @default.
• W2031848840 cites W2107420451 @default.
• W2031848840 cites W2115449326 @default.
• W2031848840 cites W2120827548 @default.
• W2031848840 cites W2124665258 @default.
• W2031848840 cites W2125001590 @default.
• W2031848840 cites W2128901862 @default.
• W2031848840 cites W2132785007 @default.
• W2031848840 cites W2150031599 @default.
• W2031848840 cites W2153379012 @default.
• W2031848840 cites W2159738093 @default.
• W2031848840 cites W2160635966 @default.
• W2031848840 cites W2163386848 @default.
• W2031848840 cites W2164824078 @default.
• W2031848840 cites W2232521529 @default.
• W2031848840 cites W2399228814 @default.
• W2031848840 cites W2078088457 @default.
• W2031848840 doi "https://doi.org/10.1161/circulationaha.110.950733" @default.
• W2031848840 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21098449" @default.
• W2031848840 hasPublicationYear "2010" @default.
• W2031848840 type Work @default.
• W2031848840 sameAs 2031848840 @default.
• W2031848840 citedByCount "27" @default.
• W2031848840 countsByYear W20318488402012 @default.
• W2031848840 countsByYear W20318488402013 @default.
• W2031848840 countsByYear W20318488402014 @default.
• W2031848840 countsByYear W20318488402015 @default.
• W2031848840 countsByYear W20318488402017 @default.
• W2031848840 countsByYear W20318488402019 @default.
• W2031848840 countsByYear W20318488402022 @default.
• W2031848840 countsByYear W20318488402023 @default.
• W2031848840 crossrefType "journal-article" @default.
• W2031848840 hasAuthorship W2031848840A5012456201 @default.
• W2031848840 hasAuthorship W2031848840A5012706547 @default.
• W2031848840 hasAuthorship W2031848840A5016716924 @default.
• W2031848840 hasAuthorship W2031848840A5021133301 @default.
• W2031848840 hasAuthorship W2031848840A5022002853 @default.
• W2031848840 hasAuthorship W2031848840A5024193392 @default.
• W2031848840 hasAuthorship W2031848840A5027291703 @default.
• W2031848840 hasAuthorship W2031848840A5039972459 @default.
• W2031848840 hasAuthorship W2031848840A5048687590 @default.
• W2031848840 hasAuthorship W2031848840A5070754331 @default.
• W2031848840 hasAuthorship W2031848840A5072521028 @default.
• W2031848840 hasAuthorship W2031848840A5083447391 @default.
• W2031848840 hasAuthorship W2031848840A5089017943 @default.
• W2031848840 hasBestOaLocation W20318488401 @default.
• W2031848840 hasConcept C115725540 @default.
• W2031848840 hasConcept C126322002 @default.
• W2031848840 hasConcept C142724271 @default.
• W2031848840 hasConcept C164705383 @default.
• W2031848840 hasConcept C168563851 @default.
• W2031848840 hasConcept C203092338 @default.
• W2031848840 hasConcept C204787440 @default.
• W2031848840 hasConcept C27081682 @default.
• W2031848840 hasConcept C2779896295 @default.
• W2031848840 hasConcept C2780400711 @default.
• W2031848840 hasConcept C36880943 @default.
• W2031848840 hasConcept C45393284 @default.
• W2031848840 hasConcept C500558357 @default.
• W2031848840 hasConcept C71924100 @default.
• W2031848840 hasConceptScore W2031848840C115725540 @default.
• W2031848840 hasConceptScore W2031848840C126322002 @default.
• W2031848840 hasConceptScore W2031848840C142724271 @default.
• W2031848840 hasConceptScore W2031848840C164705383 @default.
• W2031848840 hasConceptScore W2031848840C168563851 @default.
• W2031848840 hasConceptScore W2031848840C203092338 @default.

• next